World Investment Advisors LLC Takes $71,000 Position in MEI Pharma, Inc. (NASDAQ:MEIP)

World Investment Advisors LLC purchased a new stake in MEI Pharma, Inc. (NASDAQ:MEIP) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 25,000 shares of the company’s stock, valued at approximately $71,000. World Investment Advisors LLC owned approximately 0.38% of MEI Pharma as of its most recent SEC filing.

Separately, Corsair Capital Management L.P. acquired a new position in shares of MEI Pharma during the 3rd quarter worth approximately $69,000. 52.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of MEI Pharma in a research note on Tuesday. They issued a “buy” rating on the stock. Three investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $7.00.

MEI Pharma Trading Down 2.8 %

Shares of MEI Pharma stock opened at $2.45 on Friday. MEI Pharma, Inc. has a twelve month low of $2.43 and a twelve month high of $6.52. The firm’s 50-day moving average price is $2.83 and its 200 day moving average price is $2.96. The firm has a market capitalization of $16.32 million, a PE ratio of -0.35 and a beta of 0.79.

MEI Pharma (NASDAQ:MEIP) last released its earnings results on Tuesday, November 12th. The company reported ($1.20) earnings per share for the quarter. On average, sell-side analysts predict that MEI Pharma, Inc. will post -5.1 EPS for the current fiscal year.

MEI Pharma Company Profile

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.